A Study to Evaluate Seroprevalence and Seroconversion of Antibodies to Adeno-Associated Virus (AAV) in Patients With Hemophilia A
NCT04560933 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 186
Last updated 2024-04-24
Summary
To quantify the seroprevalence of antibodies to AAV5, AAV6, and AAV8 and the seroconversion rate over varying follow-up intervals in subjects with hemophilia A
Conditions
Interventions
- PROCEDURE
-
Blood sample collection
Blood sample collection
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Stephen Flach, MD · Covance
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-08-25
- Primary Completion
- 2023-09-20
- Completion
- 2023-10-20
Countries
- United States
Study Locations
More Related Trials
-
Clinical and Health-related Outcome of rFVIIIFc Prophylaxis
NCT04583930 ·Status: UNKNOWN
-
Liver Biopsy Following Gene Therapy For Hemophilia
NCT05932914 ·Status: NOT_YET_RECRUITING
-
Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
NCT07080905 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia A
NCT03061201 ·Status: COMPLETED ·Phase: PHASE2
-
Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers
NCT02506023 ·Status: COMPLETED ·Phase: PHASE1
-
2-cohort Study of Adult Patients With Severe Hemophilia A in Greece
NCT02319070 ·Status: COMPLETED
-
Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5
NCT03520712 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function
NCT02225483 ·Status: COMPLETED
-
Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)
NCT05962398 ·Status: ENROLLING_BY_INVITATION
-
Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A
NCT04845399 ·Status: COMPLETED ·Phase: PHASE3
-
Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B
NCT02396342 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
ATHN 11: Liver Transplantation Outcomes Study
NCT04055051 ·Status: COMPLETED
-
A Feasibility Study to Collect Data in Patients With Haemophilia
NCT00798499 ·Status: COMPLETED
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors
NCT02622321 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A
NCT01458106 ·Status: COMPLETED ·Phase: PHASE3
-
Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A
NCT01454739 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
NCT07285460 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
NCT06003387 ·Status: RECRUITING ·Phase: PHASE3
-
Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis
NCT05022459 ·Status: RECRUITING
-
A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)
NCT03587116 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A
NCT04161495 ·Status: COMPLETED ·Phase: PHASE3
-
Females With Severe or Moderate Hemophilia A or B: A Multi-Center Study
NCT00936845 ·Status: COMPLETED
-
Study of AAV5-hFIX in Severe or Moderately Severe Haemophilia B
NCT05360706 ·Status: ACTIVE_NOT_RECRUITING
-
A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy
NCT05568459 ·Status: ACTIVE_NOT_RECRUITING
-
A Gene Therapy Study for Hemophilia B
NCT02484092 ·Status: COMPLETED ·Phase: PHASE2